Maria Carla Roncaglioni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3367513/publications.pdf

Version: 2024-02-01

79 papers

8,279 citations

257450 24 h-index 71685 **76** g-index

80 all docs

80 docs citations

80 times ranked 10004 citing authors

#	Article	IF	CITATIONS
1	High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial. International Journal of Antimicrobial Agents, 2022, 59, 106516.	2.5	32
2	Metformin use is associated with a decrease in the risk of hospitalization and mortality in ⟨scp⟩COVID⟨/scp⟩â€19 patients with diabetes: A populationâ€based study in Lombardy. Diabetes, Obesity and Metabolism, 2022, 24, 891-898.	4.4	15
3	Insulin treatment in patients with diabetes mellitus and heart failure in the era of new antidiabetic medications. BMJ Open Diabetes Research and Care, 2022, 10, e002708.	2.8	2
4	Impact of liver disease on oral anticoagulant prescription and major adverse events in patients with atrial fibrillation: analysis from a population-based cohort study. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f84-f92.	3.0	6
5	Sex-related differences in prevalence, treatment and outcomes in patients with atrial fibrillation. Internal and Emergency Medicine, 2020, 15, 231-240.	2.0	12
6	Long-Term Outcomes of a Cohort of Hypertensive Subjects in Rural Ecuador. Global Heart, 2020, 14, 373.	2.3	2
7	Treatment of venous thromboembolism in Northern Italy: A population-based study from 2013 to 2018. Thrombosis Research, 2020, 188, 97-99.	1.7	1
8	Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. Cardiovascular Diabetology, 2019, 18, 70.	6.8	46
9	Long-Term Relationship Between Atrial Fibrillation, Multimorbidity and Oral Anticoagulant Drug Use. Mayo Clinic Proceedings, 2019, 94, 2427-2436.	3.0	66
10	Peripheral arterial disease: Changes in clinical outcomes and therapeutic strategies in two cohorts, from 2002 to 2008 and from 2008 to 2014. A population-based study. European Journal of Preventive Cardiology, 2018, 25, 1735-1743.	1.8	12
11	Prevalence and management of diabetes in immigrants resident in the Lombardy Region: the importance of ethnicity and duration of stay. Acta Diabetologica, 2018, 55, 355-362.	2.5	8
12	Sex differences in stroke and major adverse clinical events in patients with atrial fibrillation: A systematic review and meta-analysis of 993,600 patients. International Journal of Cardiology, 2018, 269, 182-191.	1.7	53
13	Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet, The, 2018, 392, 387-399.	13.7	273
14	Emergency department visits in older people: pattern of use, contributing factors, geographical differences and outcomes. Aging Clinical and Experimental Research, 2017, 29, 319-326.	2.9	19
15	Criteria for the choice of anticoagulant therapy for the prevention of stroke in patients with atrial fibrillation early after the marketing of direct oral anticoagulants in Italy. European Journal of Internal Medicine, 2017, 41, e12-e14.	2.2	1
16	Diabetes mellitus: a risk factor for seizures in the elderlyâ€"a population-based study. Acta Diabetologica, 2017, 54, 863-870.	2.5	17
17	Cardiovascular complications and drug prescriptions in subjects with and without diabetes in a Northern region of Italy, in 2002 and 2012. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 54-62.	2.6	5
18	Are all people with diabetes and cardiovascular risk factors or microvascular complications at very high risk? Findings from the Risk and Prevention Study. Acta Diabetologica, 2017, 54, 123-131.	2.5	14

#	Article	IF	Citations
19	Response to " Dementia and death: Separate sides of the same Atrial Fibrillation coin?― International Journal of Cardiology, 2017, 227, 190.	1.7	o
20	Outcomes in patients hospitalized for heart failure and chronic obstructive pulmonary disease: differences in clinical profile and treatment between 2002 and 2009. European Journal of Heart Failure, 2016, 18, 840-848.	7.1	23
21	Risk of dementia and death in patients with atrial fibrillation: A competing risk analysis of a population-based cohort. International Journal of Cardiology, 2016, 220, 440-444.	1.7	28
22	Comparison of Health Care Resource Utilization by Immigrants Versus Native Elderly People. Journal of Immigrant and Minority Health, 2016, 18, 1-7.	1.6	14
23	Improving cardiovascular prevention in general practice: Results of a comprehensive personalized strategy in subjects at high risk. European Journal of Preventive Cardiology, 2016, 23, 947-955.	1.8	22
24	Effectiveness, safety and feasibility of an evidence-based insulin infusion protocol targeting moderate glycaemic control in intensive cardiac care units. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 117-124.	1.0	5
25	Effectiveness of a Nurse-Managed Protocol to Prevent Hypoglycemia in Hospitalized Patients with Diabetes. Journal of Diabetes Research, 2015, 2015, 1-8.	2.3	7
26	Epidemiologic Trends in Hospitalized Ischemic Stroke from 2002 to 2010: Results from a Large Italian Population-Based Study. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 1917-1923.	1.6	21
27	A multicenter observational study on the management of hyperglycemia in patients with acute coronary syndrome. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 916-923.	2.6	5
28	Diabetes mellitus as risk factor for atrial fibrillation hospitalization: Incidence and outcomes over nine years in a region of Northern Italy. Diabetes Research and Clinical Practice, 2015, 109, 476-484.	2.8	27
29	A Polypill Strategy to Improve Adherence. Journal of the American College of Cardiology, 2014, 64, 2071-2082.	2.8	290
30	Changes in prescribing patterns and clinical outcomes in elderly diabetic patients in 2000 and 2010: analysis of a large Italian population-based study. European Journal of Clinical Pharmacology, 2014, 70, 965-974.	1.9	7
31	Elevated risk of death and major cardiovascular events in subjects with newly diagnosed diabetes: Findings from an administrative database. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 263-270.	2.6	11
32	Sex differences in cardiovascular outcomes, pharmacological treatments and indicators of care in patients with newly diagnosed diabetes: Analyses on administrative database. European Journal of Internal Medicine, 2014, 25, 270-275.	2.2	22
33	n–3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors. New England Journal of Medicine, 2013, 368, 1800-1808.	27.0	464
34	n–3 Fatty Acids in Patients with Cardiac Risk Factors. New England Journal of Medicine, 2013, 369, 780-782.	27.0	8
35	Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet, The, 2012, 379, 1602-1612.	13.7	743
36	Prevalence, incidence and mortality of diagnosed diabetes: evidence from an Italian populationâ€based study. Diabetic Medicine, 2012, 29, 385-392.	2.3	64

#	Article	IF	Citations
37	The Fixed-dose Combination Drug for Secondary Cardiovascular Prevention project: Improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives. American Heart Journal, 2011, 162, 811-817.e1.	2.7	34
38	Trends in drug prescriptions to diabetic patients from 2000 to 2008 in Italy's Lombardy Region: A large population-based study. Diabetes Research and Clinical Practice, 2011, 93, 123-130.	2.8	40
39	Transition From Intravenous to Subcutaneous Insulin. Diabetes Care, 2011, 34, 1445-1450.	8.6	46
40	Hyperglycemia During Acute Coronary Syndrome: A Nurse-Managed Insulin Infusion Protocol for Stricter and Safer Control. European Journal of Cardiovascular Nursing, 2009, 8, 182-189.	0.9	12
41	Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, The, 2009, 373, 1849-1860.	13.7	3,100
42	Diagnostic evaluation of people with hypertension in low income country: cohort study of "essential" method of risk stratification. BMJ: British Medical Journal, 2008, 337, a1387-a1387.	2.3	9
43	Response to Naunton and Duyvendak re "Appropriate use of antiplatelets: is prescription in daily practice influenced by the global cardiovascular risk?― European Journal of Clinical Pharmacology, 2006, 62, 79-80.	1.9	6
44	Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men. JAMA - Journal of the American Medical Association, 2006, 295, 306.	7.4	681
45	Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients' risk level. Vascular Health and Risk Management, 2006, 2, 507-514.	2.3	18
46	Appropriate use of antiplatelets: is prescription in daily practice influenced by the global cardiovascular risk?. European Journal of Clinical Pharmacology, 2005, 61, 595-601.	1.9	10
47	How general practitioners perceive and grade the cardiovascular risk of their patients. European Journal of Cardiovascular Prevention and Rehabilitation, 2004, 11, 233-238.	2.8	15
48	People's perception of their overall coronary risk: an Italian experience. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2004, 5, 16-21.	0.1	2
49	Primary Prevention of Cardiovascular Events With Low-Dose Aspirin and Vitamin E in Type 2 Diabetic Patients. Diabetes Care, 2003, 26, 3264-3272.	8.6	391
50	Long-term vitamin E supplementation fails to reduce lipid peroxidation in people at cardiovascular risk: analysis of underlying factors. Current Controlled Trials in Cardiovascular Medicine, 2002, 3, 5.	1.5	12
51	Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general Practice. Lancet, The, 2001, 357, 89-95.	13.7	985
52	Antioxidant strategy for cardiovascular disease. Lancet, The, 2001, 357, 1706.	13.7	2
53	Clinical Outcome and its Predictors in 1560 Patients with Critical Leg Ischaemia. European Journal of Vascular and Endovascular Surgery, 1999, 18, 401-410.	1.5	107
54	Health inequalities in Italy. Lancet, The, 1997, 350, 1557-1558.	13.7	0

#	Article	IF	Citations
55	Long-term mortality and its predictors in patients with critical leg ischaemia. European Journal of Vascular and Endovascular Surgery, 1997, 14, 91-95.	1.5	100
56	Thrombolytic therapy. From myocardial to cerebral infarction. Italian Journal of Neurological Sciences, 1996, 17, 5-21.	0.1	6
57	A prospective epidemiological survey of the natural history of chronic critical leg ischaemia. European Journal of Vascular and Endovascular Surgery, 1996, 11, 112-120.	1.5	23
58	Dissent: an alternative interpretation of MAST-I. Lancet, The, 1995, 346, 1515.	13.7	29
59	Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction. Journal of the American College of Cardiology, 1990, 16, 1553-1560.	2.8	53
60	Evidence of a warfarin-sensitive cancer procoagulant in V2 carcinoma. Haematologica, 1989, 74, 143-7.	3.5	3
61	Moderate anticoagulation by salicylate prevents thrombosis without bleeding complications. Biochemical Pharmacology, 1988, 37, 4743-4745.	4.4	6
62	Several murine metastasizing tumors possess a cysteine proteinase with cancer procoagulant characteristics. International Journal of Cancer, 1987, 39, 774-777.	5.1	21
63	Increased susceptibility to the anticoagulant effect of warfarin in mice bearing the lewis lung carcinoma. Biochemical Pharmacology, 1986, 35, 3239-3242.	4.4	O
64	The vitamin k-antagonism of salicylate and warfarin. Thrombosis Research, 1986, 42, 727-736.	1.7	16
65	Vitamin K-Dependent Procoagulant in Cancer Cells: A Potential Target for the Antimetastatic Effect of Warfarin?. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1986, 16, 288-294.	0.3	2
66	Î ³ -Glutamyl Carboxylase Activity in Experimental Tumor Tissues: A Biochemical Basis for Vitamin K Dependence of Cancer Procoagulant. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1986, 16, 295-299.	0.3	3
67	Stroke in two young siblings with congenital dysfibrinogenemia. Italian Journal of Neurological Sciences, 1983, 4, 229-232.	0.1	9
68	Lack of interaction of heparin with ADP and prostacyclin on rat platelets. Thrombosis Research, 1983, 31, 397-400.	1.7	5
69	Warfarin-induced accumulation of vitamin K-dependent proteins comparison between hepatic and non-hepatic tissues. Biochemical and Biophysical Research Communications, 1983, 114, 991-997.	2.1	16
70	Heparin Counteracts the Antiaggregating Effect of Prostacyclin by Potentiating Platelet Aggregation. Thrombosis and Haemostasis, 1983, 49, 081-083.	3.4	18
71	Thromboxane Synthetase Inhibition Results in Increased Platelet Sensitivity to Prostacyclin. Thrombosis and Haemostasis, 1982, 47, 294-294.	3.4	17
72	Oral contraceptives and the prothrombin time BMJ: British Medical Journal, 1980, 280, 332-333.	2.3	0

#	Article	IF	CITATIONS
73	Increased PGI2 activity in venous tissues from rats on oral contraceptives is not prevented by heparin administration before vessel isolation. Thrombosis Research, 1980, 18, 895-896.	1.7	3
74	Plasmatic and vascular factors of the hemostatic system in rats receiving an estrogen-progestogen combination. Contraception, 1980, 22, 249-257.	1.5	2
75	Increased prostacyclin-like activity in vascular tissues from rats on long-term treatment with an destrogen-progestagen combination. Thrombosis Research, 1979, 14, 793-797.	1.7	34
76	In vitro effect of suloctidil on 14C-5-hydroxytryptamine uptake and liberation in rat platelets. Pharmacological Research Communications, 1977, 9, 315-324.	0.2	8
77	Effects of trazodone on serotonin in the brain and platelets of the rat. Biochemical Pharmacology, 1976, 25, 13-16.	4.4	59
78	Defective ristocetin and bovine factor VIII-induced platelet aggregation in normal rats. Experientia, 1975, 31, 500-502.	1.2	20
79	A peculiar haemostatic mechanism in the rat?. Thrombosis Research, 1975, 6, 201-202.	1.7	5